Alder raises $40M
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Alder Biopharmaceuticals
|
$40M
|
Delphi Ventures and TPG Biotech |
Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases. " |
|
Bridge Laboratories
|
$18M
|
Unnamed |
Bridge Laboratories will be expanding a toxicology lab in Beijing, China, and continue to grow U.S. operations. |
|
Novamed
|
$13.8M
|
Fidelity Asia Ventures and Fidelity Biosciences |
The company will use the proceeds to finance the in-licensing of new molecules for China, expand sales and distribution operations and strengthen medical research and development capacity. |
|
Caprotec Bioanalytics
|
$8.8M
|
Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors |
The money will be used to further development and marketing of its platform technology for analyzing complex protein mixtures. |
|
PeptImmune
|
$8.2M
|
New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital |
The funding will be used to advance clinical development of Peptimmune's multiple sclerosis treatment, PI-2301. |